Phase III/IV trial of Triumeq (abacavir/dolutegravir/lamivudine) in HIV meets primary endpoint- ViiV Healthcare

ViiV Healthcare announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1. The study included 277 adults who remained on their existing ART to 24 weeks.

STRIIVING met its primary endpoint, demonstrating that viral suppression was non-inferior for patients switching to abacavir/dolutegravir/lamivudine (HIV RNA <50 copies/mL 85% (abacavir/dolutegravir/lamivudine) vs. 88% (existing ART). No patients had protocol defined virologic failure (confirmed plasma HIV-1 RNA >400 copies/mL) and therefore no patients were evaluated for treatment-emergent resistance in either arm. Furthermore, statistically, the treatment satisfaction score improved significantly more for those patients switching to once-daily abacavir/dolutegravir/lamivudine from their established regimen, as assessed by the HIV Treatment Satisfaction Questionnaire.

Patients switching to abacavir/dolutegravir/lamivudine reported more adverse events (AEs) leading to withdrawal compared with those who continued on their established regimen.